KR20050028272A - Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging - Google Patents
Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging Download PDFInfo
- Publication number
- KR20050028272A KR20050028272A KR1020030064952A KR20030064952A KR20050028272A KR 20050028272 A KR20050028272 A KR 20050028272A KR 1020030064952 A KR1020030064952 A KR 1020030064952A KR 20030064952 A KR20030064952 A KR 20030064952A KR 20050028272 A KR20050028272 A KR 20050028272A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- diabetes
- diet
- functional food
- present
- Prior art date
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title abstract description 22
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 17
- 235000005911 diet Nutrition 0.000 title abstract description 10
- 230000037213 diet Effects 0.000 title abstract description 10
- 230000002292 Radical scavenging effect Effects 0.000 title abstract 3
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract 3
- 241001672694 Citrus reticulata Species 0.000 claims abstract description 14
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 13
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 7
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052737 gold Inorganic materials 0.000 claims description 11
- 239000010931 gold Substances 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 229910052709 silver Inorganic materials 0.000 claims description 10
- 239000004332 silver Substances 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 239000011435 rock Substances 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 241000237509 Patinopecten sp. Species 0.000 claims description 4
- 235000020637 scallop Nutrition 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims 3
- 235000007882 dietary composition Nutrition 0.000 claims 1
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 abstract description 2
- 241001466453 Laminaria Species 0.000 abstract 1
- 244000167230 Lonicera japonica Species 0.000 abstract 1
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 1
- 244000302544 Luffa aegyptiaca Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 18
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 18
- 229960001052 streptozocin Drugs 0.000 description 18
- 235000012000 cholesterol Nutrition 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000008103 glucose Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 8
- 230000007721 medicinal effect Effects 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 201000002451 Overnutrition Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001164 bioregulatory effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020823 overnutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- YZBHTULXQCHTHI-UHFFFAOYSA-N C(C)OC(CC(OCC)OCC)OCC.C(C)OC(CC(OCC)OCC)OCC Chemical compound C(C)OC(CC(OCC)OCC)OCC.C(C)OC(CC(OCC)OCC)OCC YZBHTULXQCHTHI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 다이어트, 항당뇨, 고지혈증 및 항산화에 효과적인 기능성 식품에 관한 것이다. 더욱 상세하게는, 본 발명은 혈중 글루코스(glucose), 트리글리세라이드(triglyceride) 및 콜레스테롤(cholesterol) 값을 낮추는 백강잠, 미삼, 연자육, 우절, 사과락, 귤핵, 곤포, 길경 및 금은화를 포함하여 이루어지는 생약성분들을 복합처방함으로써 다이어트, 항당뇨, 고지혈증 및 항산화에 효과적인 기능성 식품에 관한 것이다.The present invention relates to a functional food effective for diet, antidiabetic, hyperlipidemia and antioxidant. More specifically, the present invention includes a herbal medicine including white asleep, rice bran, lotus root, falcon, apple rock, mandarin kernels, bales, gilyeong and gilding to lower blood glucose, triglyceride and cholesterol values. The present invention relates to a functional food that is effective in diet, antidiabetic, hyperlipidemia and antioxidant by compounding the ingredients.
현대 산업사회의 발달로 경제적인 여유와 문화적인 혜택을 누리고 있으나, 이로 인한 환경오염 또는 과 영양화로 인하여 우리들의 생명이 직접 또는 간접적으로 위협을 받고 있으며, 이에 대응하여 현대인들은 건강에 대하여 관심이 그 어느때보다 고조되고 있으며, 이에 따라 건강유지나 생체리듬을 조절하는 효능이 있는 기능성 식품 또는 그런 약품들에 대한 관심이 높아지고 있다.Although economic development and cultural benefits are enjoyed by the development of modern industrial society, our lives are directly or indirectly threatened by environmental pollution or over-nutrition, and in response, modern people are concerned about their health. More than ever, there is a growing interest in functional foods or such drugs that are effective in maintaining health or regulating biorhythms.
한편, 식품의 기능에 있어서 최근까지는 영양기능과 그 맛 또는 조직이 인체의 감가에 미치는 기능 등이었으나, 현재는 식품의 기능범위가 유해물질의 중화, 해독, 배설, 혈압, 혈당, 콜레스테롤의 감소, 비만방지 및 다이어트 등의 생체 조절기능을 가지는 기능성 식품으로 발전하고 있다.On the other hand, in the function of food until recently, the function of nutrition and its taste or tissues on the depreciation of the human body, etc., but the range of the function of food currently is to neutralize, detox, excrete, blood pressure, blood sugar, cholesterol, It is developing into a functional food having bioregulatory functions such as obesity prevention and diet.
기능성 식품이란 생체방어, 면역, 질병의 예방 및 치료, 병후의 회복, 노화 억제등 생체조절기능을 가지는 식품을 말하며, 장기적으로 복용하였을 때 인체에 무해하여야 한다.Functional food refers to foods that have bioregulatory functions such as biological defense, immunity, prevention and treatment of diseases, recovery of symptoms, and inhibition of aging, and should be harmless to the human body when taken in the long term.
현재 대부분의 성인병중 가장 문제가 되는 질병은 영양과잉 및 운동부족으로 인한 비만에 의해서 야기되는 순환기 질병 및 당뇨병이다. 이것을 예방 및 치료하기 위한 가장 바람직한 방법은 기능성 식품을 이용하여 질병을 미연에 방지하는 것이며, 이들의 치료 및 예방으로 사용할 수 있는 기능성 식품으로는 옛날부터 자양강장제로 사용되던 오가피, 두충, 산수유, 오미자, 구기자, 인삼 및 박과 식물등이 있다.Currently, the most problematic diseases of most adult diseases are circulatory diseases and diabetes caused by obesity due to overnutrition and lack of exercise. The most preferable way to prevent and treat this is to prevent diseases in advance by using functional foods, and functional foods that can be used for the treatment and prevention of them are organza, tofu, cornus and omija, which have been used as nutrient tonics since ancient times. , Wolfberry, ginseng and gourd.
당뇨병을 예방하기 위해서는 가장 먼저 탄수화물을 많이 섭취하여서는 안되며, 섭취하여도 흡수가 되지 않아야 한다. 이런 효과가 있는 식품으로는 여러 가지가 있을 수 있으나, 현재 활성실험 및 본초학적 고찰을 통하여 백감장, 미삼, 연자육, 우절, 사과락, 귤핵, 곤포 및 길경들이 알려져 있다.To prevent diabetes, you should not consume too much carbohydrates first, and it should not be absorbed even if you eat it. There may be a variety of foods that have such an effect, but currently, baekgamjang, samsam, yeonjak, pilgrim, apple rock, mandarin kernels, bales, and Gilkyung are known through active experiments and herbal studies.
이런 식물들의 효과는 그 추출물이 장에 작용하여 당, 중성지방, 콜레스테롤이 흡수를 억제하거나 흡수되어 역시 혈당, 중성지방 및 콜레스테롤의 양을 효과적으로 떨어뜨리는 것으로 알려져 있다.The effect of these plants is known that the extract acts on the intestine, inhibiting or absorbing the absorption of sugar, triglycerides and cholesterol, which effectively reduces the amount of blood sugar, triglycerides and cholesterol.
이상과 같이 현대인의 가장 큰 문제점은 비만으로 인한 당뇨병등의 질병이며, 이 질병을 예방 또는 치료하기 위해서는 탄수화물을 먹었을 때 소장에서 탄수화물과 상경적으로 작용 흡수를 억제하는 것이 가장 이상적이다. 우리나라에서는 동고자 또는 홍삼등과 같은 엑기스만이 기능성 식품으로 판매가 되고 있으나, 단일 생약제 사용함으로써 단일생약제에 의한 특정 기능만을 기대할 수 있을 뿐 만 아니라, 단일 생약제가 갖을 수 있는 단점을 보안할 수 없는 단점이 있었다.As mentioned above, the biggest problem of modern people is a disease such as diabetes due to obesity, and in order to prevent or treat this disease, it is most ideal to inhibit the absorption of the carbohydrates in the small intestine when the carbohydrate is eaten. In Korea, only extracts such as bundling or red ginseng are sold as functional foods.However, by using a single herbal medicine, not only certain functions can be expected by a single herbal medicine, but also the disadvantages of a single herbal medicine cannot be secured. There was this.
이에 본 발명은 앞서 설명한 바와 같은 종래 기술의 문제점을 더욱 효율적으로 해결하기 위하여 제공된 것으로써,Accordingly, the present invention is provided to more efficiently solve the problems of the prior art as described above,
본 발명의 목적은 혈중 글루코스(glucose), 트리글리세라이드(triglyceride) 및 콜레스테롤(cholesterol) 값을 낮추는 백강잠, 미삼, 연자육, 우절, 사과락, 귤핵, 곤포, 길경 및 금은화를 포함하여 이루어지는 생약성분들을 복합처방함으로써 다이어트, 항당뇨, 고지혈증 및 항산화에 효과적인 기능성 식품을 제공하기 위한 것이다.An object of the present invention is a combination of herbal ingredients consisting of baekpja, misam, lotus, chops, apple rock, mandarin kernels, bales, gilyeong and gold and silver coin to lower blood glucose, triglyceride and cholesterol (cholesterol) values The prescription is to provide a functional food effective for diet, antidiabetic, hyperlipidemia and antioxidants.
상기 목적 및 기타 목적들은 하기에 설명되는 본 발명에 의하여 모두 달성될 수 있다.The above and other objects can be achieved by the present invention described below.
상기한 목적을 달성하기 위하여, 본 발명에 따른 다이어트, 항당뇨, 고지혈증 및 항산화제용 조성물은 백강잠 5 내지 15중량% , 미삼 5 내지 15중량%, 연자육 5 내지 15중량%, 우절 5 내지 15중량%, 사과락 5 내지 15중량%, 글핵 5 내지 15량%, 곤포 5 내지 15중량%, 길경 5 내지 15중량% 및 금은화 5 내지 15중량%를 포함하여 이루어질 수 있다.In order to achieve the above object, the diet, antidiabetic, hyperlipidemia and antioxidant composition according to the present invention is 5 to 15% by weight, 5 to 15% by weight, 5 to 15% by weight, 5 to 15% by weight of scapula 5 to 15% by weight, 5 to 15% by weight, 5 to 15% by weight, 5 to 15% by weight, 5 to 15% by weight, and 5 to 15% by weight of gold coins.
상기 조성물에 부가첨가제로서 과즙 및 향료가 더 포함될 수 있다.Juice and flavoring may be further included in the composition as an additive.
이하, 본 발명에 대하여 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명에서는 소장에서 탄수화물 및 지방에 대하여 상경적으로 작용해 흡수를 저해하고 또한 흡수되어 혈중 글루코스, 트라이그리세라이드 및 콜레스테롤 수치를 낮추는 생약을 이용한다. 이에 본발명의 바람직한 생약으로서 백감장, 미삼, 연자육, 우절, 사과락, 귤핵, 곤포, 길경, 금은화 등이 있다.In the present invention, herbal medicines that act on the carbohydrates and fats in the small intestine, inhibit absorption and are also absorbed to lower blood glucose, triglycerides and cholesterol levels. Preferred herbal medicines of the present invention include Baekgamjang, misam, lotus root, pilgrim, apple rock, tangerine core, packing, Gilkyung, gold and silver coins.
백감장은 누에유충이 백강병균의 감염에 의한 백강병으로 경직사한 충체이다. 이는 혈당을 낮추는 작용이 있고 급성 유선염의 치료효과가 있다. 본 발명에따른 백감장은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Baekgamjang is a fungus in which silkworm larvae stiffen with leukemia caused by infection with Leukemia bacteria. It lowers blood sugar and has a therapeutic effect for acute mastitis. Baekjang according to the present invention is used in 5 to 15% by weight, more preferably 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
미삼은 인삼의 잔뿌리를 말하는데 값이 저렴하면서도 인삼의 효과를 얻을 수 있어 일반적으로 많이 사용되며, 항이 순하고 신선한 수삼의 어린 것이 좋다. 미삼은 피로회복, 체력증강, 보혈증강에 효험이 있는 것으로 알려져 있다. 본 발명에 따른 미삼은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Misam refers to the roots of ginseng, which is cheap and can get the effect of ginseng, and is generally used a lot. Misam is known to be effective in fatigue recovery, physical strength enhancement, and blood pressure enhancement. Misam according to the present invention is used 5 to 15% by weight, more preferably 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
연꽃의 열매를 연자육(蓮子肉)이라 하는데, 대하가 있을 경우 끓여 마시면 효과를 볼 수 있으며, 전반적으로 강장, 자양 작용이 뛰어나 산후 여성에게 권할만 하다. 심장(心廳)을 맑게 하는 작용이 있어 불면증이나 심계(心悸)증 등이 있을 시도 사용할 수 있다. 본 발명에따른 연자육은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.The fruit of lotus is called Yeonjakyuk (蓮 子 肉), if you have a large boil and drink to see the effect, overall tonic, nourishing action is excellent for postpartum women. There is a function to clear the heart (廳) can be used to try insomnia or heart disease (心悸). Soft meat according to the present invention is used in 5 to 15% by weight, more preferably 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
연뿌리를 한방에서는 '우절'이라고 하는데, 동의보감에는 우절의 특성으로서 각종 출혈 질환, 빈혈등에 좋을 뿐만 아니라 우수한 강정작용까지 있으며 아울러 비위장 소화기 계통에도 우수한 효과가 기재되어 있다. 본 발명에따른 우절은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.The root of the lotus root is called 'wool' in oriental medicine, and it is not only good for various bleeding diseases, anemia, etc., but also has an excellent gangjeong effect, as well as excellent effect on the non-gastrointestinal digestive system. The falcon according to the present invention is used at 5 to 15% by weight, more preferably at 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
사과락은 일명 수세미라고 하며 옹저창종(癬疽瘡腫) 및 헛배부름에 좋은 효과가 있는 것으로 알려져 있다. 본 발명에따른 사과락은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중랑%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Apple-lac, also known as loofah, is known to have a good effect on the stalk of swelling and flatulence. Apple Lac according to the present invention is used in 5 to 15% by weight, more preferably in 10 to 13 weight percent. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
귤핵은 귤나무의 종자이며 고환염, 유방염, 요통등에 유효한 약리성질을 갖는다. 본 발명에따른 귤핵은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Tangerine nucleus is a seed of the tangerine tree and has pharmacological properties effective for testicles, mastitis and back pain. Tangerine core according to the present invention is used in 5 to 15% by weight, more preferably in 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
곤포는 칼로리가 낮고 무기질이 풍부한 알칼리성 식품으로 칼슘이 풍부하여 이와 뼈를 튼튼하게 하고, 혈압을 내려 주는 성분(라미닌)이 있어 고혈압에 좋고, 항암 작용이 있다. 갑상선 기능부족과 항진을 개선하고 혈지를 제거해주는 작용이 있으며 치질성 혈변 동맥출혈시 지혈 작용 및 열을 내리고 이뇨작용도 있다, 본 발명에따른 곤포는 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Packing is a low-calorie, mineral-rich alkaline food, rich in calcium, strong bones, and lowers blood pressure (laminin), which is good for high blood pressure and has anticancer activity. There is an action to improve the thyroid dysfunction and hyperactivity, and remove the blood, and hemorrhoidal hemorrhagic hemorrhagic artery bleeding and fever and diuretic action, the packing according to the present invention is used in 5 to 15% by weight, more preferably Is used in 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
길경은 배농, 거담, 기관지염, 천식, 소염등의 호흡기계 질환에 사용되어온 생약제로서 다양한 약리작용을 갖고 있는 것으로 알려져 있다. 길경의 주요 약리성분은 테르펜계 사포닌으로서 용혈, 국소자극, 진해, 거담작용, 중추신경억제작용, 급만성 염증에 대한 항염증작용, 항알레르기, 항궤양 및 위액분비억제작용, 혈관을 확장하여 혈압을 낮추는 항콜린작용, 혈당강하작용, 콜레스테롤 대사개선작용이 있는 것으로 밝혀졌다[Lgarashi, K., Sogoigaku, 3, 1(1951) 및 이은방, 생약학회지, 5, 49(1974)]. 본 발명에따른 길경은 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량%이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Gilkyung is known as a herbal medicine that has been used in respiratory diseases such as drainage, expectoration, bronchitis, asthma and anti-inflammatory. The main pharmacological components of Gilkyung are terpene-based saponins, hemolysis, local stimulation, antitussive action, expectoration, central nervous system depression, anti-inflammatory action against acute inflammation, anti-allergic, anti-ulcer and gastric juice secretion, blood vessel expansion It has been shown to have anticholinergic, hypoglycemic and cholesterol metabolism lowering effects (Lgarashi, K., Sogoigaku, 3, 1 (1951) and Lee Eun-bang, Journal of Pharmacognosy, 5, 49 (1974)). Gil length according to the present invention is used in 5 to 15% by weight, more preferably in 10 to 13% by weight. When it is used below 5% by weight, it is difficult to expect the medicinal effect.When it is used above 15% by weight, it is not supplemented with other herbal ingredients.
금은화는 인동초라고도 한다. 단 맛과 찬 기운을 가져, 열을 내리고 해독작용을 하며, 염증을 삭이고, 종기의 고름을 배출시키는 작용을 한다. 감기, 설사, 열성질환, 화농성피부질환 등에 광범위하게 사용한다. 본 발명에따른 금은화는 5 내지 15중량%로 사용하며, 보다 바람직하게는 10 내지 13중량%로 사용한다. 5중량% 이하 사용시에는 약효를 기대하기 어렵고 15중량%이상 사용시에는 다른 생약성분과의 보완이 이루어지지 않는다.Gold and silver coins are also called Indongcho. It has a sweet and cold energy to lower heat and detoxification, to inflame inflammation, to discharge the boil pus. It is widely used for colds, diarrhea, recessive diseases and purulent skin diseases. Gold and silver coins according to the present invention is used in 5 to 15% by weight, more preferably 10 to 13% by weight. When using less than 5% by weight it is difficult to expect the efficacy, and when used more than 15% by weight does not make up with other herbal ingredients.
또한 본발명의 조성물에 과즙 또는 향료를 공지의 방법으로 첨가함으로써 맛 및 향을 증진시킬 수 있다.It is also possible to enhance the taste and aroma by adding the fruit juice or flavoring to the composition of the present invention in a known manner.
이하 본 발명을 하기 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
[실시예 1]Example 1
백감장 10g, 미삼 10g, 연자육 10g, 우절 10g, 사과락 10g, 귤핵 10g, 곤포 10g, 길경 10g을 혼합하여 200ml의 에탄올을 부은다음 70℃에서 3시간동안 가열하열다. 영하 40℃에서 15시간 급속동결 농축한 후, 0.23토르 이하의 압력하에서 35시간 이상 냉동건조기에서 건조하여 8g의 분말을 얻었다.10g Baekjangjang, 10g of ginseng, 10g of lotus root, 10g of scallop, 10g of apple rock, 10g of tangerine kernel, 10g of bale, 10g of mixed length, pour 200ml of ethanol and heat it at 70 ℃ for 3 hours. After freezing and concentrating for 15 hours at -40 ° C, the resultant was dried in a freeze dryer for at least 35 hours under a pressure of 0.23 Torr or less to obtain 8 g of powder.
[실시예 2]Example 2
백감장 10g, 미삼 10g, 연자육 10g, 우절 10g, 사과락 10g, 귤핵 10g, 곤포 10g, 길경 10g, 금은화 10g을 혼합하여 100ml의 에탄올을 첨가한 것만을 제외하고는 실시예 1과 동일 방법으로 진행하여 9g의 분말을 얻었다.Proceed in the same manner as in Example 1, except that 100 g of baekgamjang, 10 g of ginseng, 10 g of yeonjak, 10 g of scallions, 10 g of apple rock, 10 g of tangerine kernels, 10 g of bales, 10 g of Gilyeong, 10 g of gold and silver coin were added. 9g of powder was obtained.
[실험예]Experimental Example
상기 실시예들에 의해서 제조된 분말들에 대하여 항산화능 실험, 고지혈증 및 당뇨유발 쥐에 미치는 영향 실험 및 체중감소 실험을 실시하였다.Powders prepared by the above examples were tested for antioxidant activity, hyperlipidemia and diabetes-induced effects and weight loss.
[실험예 1]Experimental Example 1
항산화능에 대하여 DPPH에 의한 항산화능 및 TBARS 분석방법을 이용한 LDL 지질과산화에 미치는 영향을 실험하였다.The effects of DPPH on antioxidant activity and LBA lipid peroxidation using TBARS assay were examined.
1) DPPH에 의한 항산화능 실험1) Antioxidant Activity Test by DPPH
도 1의 내용에 따라, Hatano 등의 방법에 의하여 각 구획(fraction)을 100, 200, 500, 1000, 2000 및 3000ppm(99.5% 에탄올)의 6가지 농도로 조제한 용액 0.1㎖(control(대조군) : 99.5% 에탄올)에 0.1mM DPPH용액(99.5% 에탄올) 1.9㎖를 가하였다. Vortex mixer로 10초간 진탕한 후 37℃에서 30분 동안 배양(incubation)시켰다. 이후 자외선 광학측정기(UV spectrophotometer)를 이용하여 515nm에서 흡광도를 측정하였다.According to the contents of FIG. 1, 0.1 mL of a solution prepared in six concentrations of 100, 200, 500, 1000, 2000 and 3000 ppm (99.5% ethanol) by the method of Hatano et al. (Control: 99.5% ethanol) was added 1.9 ml of 0.1 mM DPPH solution (99.5% ethanol). After 10 seconds shaking with the Vortex mixer was incubated for 30 minutes at 37 ℃. Thereafter, the absorbance was measured at 515 nm using an ultraviolet spectrophotometer.
양성 대조 약물로는 L-ascorbic acid를 25, 50, 100, 200ppm(99.5% 에탄올)의 4가지 농도로 조제하여 측정하였다. 각 시료의 항산화작용은 계산식 1의 DPPH에 대한 전자공여능(Electron donating ability, EDA%)과 IC50(DPPH radical 형성을 50% 억제하는데 필요한 ㎕ 농도)를 측정하였고 그 결과를 하기 표 1, 표 2, 도 3 및 도 4에 나타내었다.As a positive control drug, L-ascorbic acid was measured by preparing four concentrations of 25, 50, 100, and 200 ppm (99.5% ethanol). The antioxidant activity of each sample was measured by measuring the electron donating ability (EDA%) and IC 50 (μl concentration required to inhibit DPPH radical formation by 50%) for DPPH of Formula 1, and the results are shown in Table 1 and Table 2 below. 3 and 4 are shown.
Sample O.D. : 실시예를 가한 시험액의 흡광도Sample O.D. : Absorbance of Test Solution Added Example
Control O.D.: 실시예 대신 에탄올을 가한 시험액의 흡광도Control O.D .: Absorbance of Test Solution Added Ethanol Instead of Example
상기 표 1 및 2, 도 3 및 4에서 알 수 있듯이, 대조약물인 ascorbic acid와 비교하였을 때 실시예 2,실시예 1 순으로 활성이 나타났으며 특히 실시예 2가 DPPH에 의한 항산화능(radical scavenging activity)이 우수하였다. 또한 IC50의 경우 실시예 2가 85.31± 0.322㎍/㎖, 실시예 1이 231.05± 26.97㎍/㎖로 우수한 항산화능을 나타내었다.As can be seen in Table 1 and 2, Figures 3 and 4, the activity was shown in the order of Example 2, Example 1 compared with the control drug ascorbic acid, especially Example 2 is the antioxidant activity of DPPH (radical The scavenging activity was excellent. In the case of IC 50 , Example 2 showed an excellent antioxidant capacity of 85.31 ± 0.322 μg / ml and Example 1 of 231.05 ± 26.97 μg / ml.
2) TBARS 분석방법을 이용한 LDL 지질과산화에 미치는 영향 실험2) Influence experiment on LDL lipid peroxidation using TBARS method
도 2의 내용에 따라, 인간 혈장 LDL(Human plasma LDL(400㎍ 단백질)), 1mM CuSO4 16㎕, 농도별로 조제한 각 시료(25, 50, 100, 200, 500, 1000 및 2000ppm) 100㎕에 PBS(pH 7.4)를 섞어 전체 부피가 1ml가 되도록 하였다. Vortex mixer로 혼화하여 37℃ 수욕상에서 4시간 동안 진탕 배양하여 산화시킨 후 1mM EDTA 20㎕를 첨가하여 산화를 중지시켰다.According to the contents of FIG. 2, in 100 μl of human plasma LDL (Human plasma LDL (400 μg protein)), 16 μl of 1 mM CuSO 4 , and each sample (25, 50, 100, 200, 500, 1000 and 2000 ppm) prepared for each concentration. PBS (pH 7.4) was mixed to bring the total volume to 1 ml. The mixture was mixed with a Vortex mixer and oxidized by shaking culture for 4 hours in a 37 ° C. water bath, and then 20 µl of 1 mM EDTA was added to stop the oxidation.
산화된 LDL용액에 25% 트라이콜로아세트산(trichloroacetic acid) 1ml를 넣어 단백질을 침전시킨 후 그 상등액에 1% 티오바비튜릭산(thiobarbituric acid) 1ml를 첨가하여 95℃에서 발색시킨 후 냉각시켰다. 생성된 MDA의 양을 532nm에서 광학측정기(spectrophotometer)를 이용하여 측정하였다.1 ml of 25% trichloroacetic acid was added to the oxidized LDL solution to precipitate proteins, and 1 ml of 1% thiobarbituric acid was added to the supernatant, followed by color development at 95 ° C., followed by cooling. The amount of MDA produced was measured using a spectrophotometer at 532 nm.
MDA 표준시료로는 10nM 1,1,3,3-테트라에톡시프로판(1,1,3,3-Tetraethoxypropane) 용액을 용시 조제하여 사용하였다.As an MDA standard sample, 10 nM 1,1,3,3-tetraethoxypropane (1,1,3,3-Tetraethoxypropane) solution was prepared and used.
F: 표준시료의 흡광도 (532nm)F: absorbance of standard sample (532 nm)
f: 검체의 흡광도 (532nm)f: absorbance of the sample (532 nm)
각 시료의 LDL 지질과산화 억제효과를 비교검토하기 위해서 Cu2+에 의해 유도되는 과산화지질의 생성을 50% 억제하는데 필요한 시료의 농도(IC50)를 측정하였고 그 결과를 표 3, 표 4, 도 5 및 도 6에 나타내었다.In order to compare the LDL lipid peroxidation inhibitory effect of each sample, the concentration of the sample (IC 50 ) required to inhibit the production of lipid peroxide induced by Cu 2+ by 50% was measured and the results are shown in Table 3, Table 4, and FIG. 5 and FIG. 6.
LDL: 산화되지않은 LDLLDL: Unoxidized LDL
Ox-LDL : Cu2+ 유도 산화된 LDLOx-LDL: Cu 2+ induced oxidized LDL
[Ox-LDL]: Cu2+ 유도 산화된 LDL의 MDA[Ox-LDL]: MDA of Cu 2+ Induced Oxidized LDL
[시료 LDL]: 시료가 첨가되어 산화된 LDL의 MDA[Sample LDL]: MDA of LDL oxidized with sample added
[LDL]: 산화되지 않은 LDL의 MDA[LDL]: MDA of unoxidized LDL
IC50: Cu2+ 유도된 LDL지질 과산화작용의 50% 저해에 필요한 시료의 농도(㎍/㎖)IC 50 : Sample concentration (μg / ml) required for 50% inhibition of Cu 2+ induced LDL lipid peroxidation
상기 표 3 및 4, 도 5 및 6에서 알 수 있듯이, 대조약물인 ascorbic acid와 비교하였을 때 항산화 활성이 컸던 실시예 2 투여군의 경우 과산화지질억제 활성을 나타내었다.As can be seen in Tables 3 and 4, FIGS. 5 and 6, the Example 2 administration group, which had a large antioxidant activity compared to the control drug ascorbic acid, exhibited lipid peroxidation inhibitory activity.
[실험예 2]Experimental Example 2
고지혈증 및 당뇨유발 쥐에 미치는 영향 실험Experiments on the effects on hyperlipidemia and diabetes-induced rats
1) 실험동물1) Experimental Animal
Sprague-Dawley계 암컷 흰쥐를 한림농원에서 구입하여 24℃± 1℃하에서 1주일동안 사육하여 체중이 140± 20g되는 것을 실험실에서 사용하였다.Sprague-Dawley female rats were purchased from Hallym Farm and were bred at 24 ° C ± 1 ° C for one week and weighed 140 ± 20g in the laboratory.
2) 당뇨유발2) Induced Diabetes
스트렙토조토신(Streptozotocin) 50mg/kg을 쥐(rat)에 투여하였다. 혈당(blood glucose), 콜레스테롤(cholesterol), 트라이글라이세라이드(triglyceride)를 측정하기 위해 하대정맥에서 혈액 시료를 취하여 원심분리하여 사용하였다.Streptozotocin 50 mg / kg was administered to rats. To measure blood glucose, cholesterol, and triglyceride, blood samples were taken from the inferior vena cava and centrifuged.
3) 혈당, 콜레스테롤 및 트라이글라이세라이드3) Blood Sugar, Cholesterol and Triglycerides
혈액 시료를 상온에서 원심분리하여 GOD-glucose 분석, CHOD-PAP 콜레스테롤 분석, 그리고 GPO-PAP 트라이글라이세라이드 분석을 위해 혈청(plasma)를 일반적인 광학측정기(spectrophotometer)로 측정하였고 그 결과를 하기 표 5, 6, 7, 도 7, 8 및 9에 나타내었다. 모든 실험 결과는 평균치와 표준오차를 계산하였고, 각 군간의 차이는 student t-test를 사용하여 p값이 5%미만일 때 통계적으로 유의성이 있다고 판정하였다.Blood samples were centrifuged at room temperature to measure plasma using a conventional spectrophotometer for GOD-glucose analysis, CHOD-PAP cholesterol analysis, and GPO-PAP triglyceride analysis. , 6, 7, FIGS. 7, 8 and 9 are shown. All experimental results calculated the mean and standard error, and the differences between the groups were statistically significant when the p-value was less than 5% using the student t-test.
ㄱ) 혈액 중 혈당에 대한 작용A) action on blood glucose in the blood
대조군: 50mg/kg 스트렙토조토신(streptozotocin ip.)Control: 50 mg / kg streptozotocin (streptozotocin ip.)
각 값은 ± S.E(N=6)을 나타낸다.Each value represents ± S.E (N = 6).
음성대조군과의 유의적 차이:* p<0.05, **p<0.01Significant difference from negative control: * p <0.05, ** p <0.01
상기 표 5에서 알 수 있듯이, 스트렙토조토신(Streptozotocin) 50mg/kg을 복강 내 투여한 대조군에서는 혈당치342.00mg/dl로 정상동물의 115.6mg/dl에 비해 현저히 상승되어 고혈당이 유발된 것을 알 수 있었고, 당뇨병 치료약물인 양성 대조약물인 tolbutamide 투여군에서는 혈당치가 117.4 mg/dl로 감소됨을 알 수 있었다.As can be seen in Table 5, the control group intraperitoneally administered streptozotocin 50mg / kg blood sugar level of 342.00mg / dl was significantly elevated compared to 115.6mg / dl of normal animals was found to be induced hyperglycemia In the tolbutamide-treated group, a positive control drug for the treatment of diabetes, blood glucose levels were reduced to 117.4 mg / dl.
다음으로 당뇨병을 유발시킨 쥐에 실시예 2를 각각 100, 200 mg/kg을 투여하였을 때 제제의 혈당강하 효과가 현저하였으며, 대조약물과 비교하여 혈당이 155.67 mg/dl, 124.67 mg/dl로 용량 의존적으로 현저하게 유의성 있게 감소함을 알 수 있었다(도 7참조).Next, the hypoglycemic effect of the formulation was remarkable when the Example 2 administration of diabetes mellitus 100 and 200 mg / kg, respectively, and the blood glucose was 155.67 mg / dl, 124.67 mg / dl compared to the control drug It was found to significantly decrease significantly depending on (see FIG. 7).
ㄴ)혈청 중 총 콜레스테롤에 대한 작용B) action on total cholesterol in serum
대조군: 50mg/kg 스트렙토조토신(streptozotocin ip)Control: 50 mg / kg streptozotocin (streptozotocin ip)
각 값은 ± S.E(N=6)을 나타낸다.Each value represents ± S.E (N = 6).
음성대조군과의 유의적 차이: *p<0.05, **p<0.01Significant difference from negative control: * p <0.05, ** p <0.01
상기 표 6에서 알 수 있듯이, 스트렙토조토신(Streptozotocin) 50mg/kg을 복강 내 투여한 대조군에서는 콜레스테롤치 70.0mg/dl로 정상동물의 58.2mg/dl에 비해 약간 상승되어 당뇨병을 유발시킬 경우 콜레스테롤 농도에는 영향을 주지 않는 것을 알 수 있었으며, 당뇨병 치료약인 tolbutamide 투여군에서는 콜레스테롤치가 76.4 mg/dl로 변동이 없음을 알 수 있어 혈중 콜레스테롤에는 영향을 주지 못하는 것을 알 수 있다.As can be seen in Table 6, in the control group intraperitoneally administered streptozotocin 50mg / kg cholesterol level 70.0mg / dl slightly increased compared to 58.2mg / dl of normal animals cholesterol concentration when causing diabetes The tolbutamide treatment group, which is a diabetic drug, showed no change to 76.4 mg / dl, indicating that it did not affect blood cholesterol.
한편 당뇨병을 유발시킨 쥐에 실시예 2를 100, 200mg/kg을 투여 하였을 때 콜레스테롤 저하 활성을 나타내었고, 67.8, 61.5mg/dl으로 용량 의존적으로 감소함을 알 수 있었다(도 8 참조).On the other hand, when administration of 100, 200mg / kg of Example 2 to the mice that induced diabetes showed cholesterol-lowering activity, it can be seen that the dose-dependent decrease to 67.8, 61.5mg / dl (see Figure 8).
ㄷ) 혈청 중 트라이글리세라이드(triglyceride)에 대한 작용C) action on triglycerides in serum
대조군: 50mg/kg 스트렙토조토신(streptozotocin ip)Control: 50 mg / kg streptozotocin (streptozotocin ip)
50% 메탄올 추출물50% Methanol Extract
각 값은 ± S.E(N=6)을 나타낸다.Each value represents ± S.E (N = 6).
음성대조군과의 유의적 차이:* p<0.05,** p<0.01Significant difference from negative control: * p <0.05, ** p <0.01
상기 표 7에서 알 수 있듯이, 스트렙토조토신(Streptozotocin) 50mg/kg을 복강 내 투여한 대조군에서는 트리글리세라이드치 123.0mg/dl로 정상동물의 60.4mg/dl에 비해 현저히 상승되는 것을 알 수 있었고, 당뇨병 치료약인 tolbutamide투여군에서는 중성지방인 트리글리세라이드치가 74.2mg/dl로 현저히 감소됨을 알수 있었다. 한편 당뇨병을 유발시킨 쥐에 실시예 2를 100, 200mg/kg을 투여 하였을 때 트리글리세라이드치가 66.3, 62.3mg/dl로 감소되어 활성이 좋은 것으로 나타났다.As can be seen in Table 7, in the control group intraperitoneally administered streptozotocin 50mg / kg triglyceride value 123.0mg / dl was significantly increased compared to 60.4mg / dl of normal animals, diabetes In the tolbutamide group, the triglyceride level of triglyceride was significantly reduced to 74.2mg / dl. Meanwhile, when 100 and 200 mg / kg of Example 2 was administered to rats that induced diabetes, triglyceride levels were reduced to 66.3 and 62.3 mg / dl, indicating good activity.
한편 항산화 및 과산화지질 억제작용이 좋은 실시예 2 투여군의 경우 당뇨병 유발 혈액 중 트리글리세라이드에는 활성이 낮았으며 특히 용량을 증가시킬수록 콜레스테롤의 농도와 같이 트리글세라이드농도 역시 증가시키는 것으로 나타났다(도 9 참조).On the other hand, the Example 2 administration group having good antioxidant and lipid peroxidation inhibitory activity showed low activity in triglycerides in diabetic-induced blood, and in particular, as the dose was increased, the triglyceride concentration was increased as well as the concentration of cholesterol (see FIG. 9). ).
[실험예 3]Experimental Example 3
체중감소 실험Weight loss experiment
1) 실험동물1) Experimental Animal
ICR계 쥐(mouse) 수컷을 한림농원에서 구입하여 24℃± 1℃하에서 1주일동안 사육하여 체중이 24 ± 2g되는 것을 실험실에서 사용하였다.ICR mice were purchased at Hallym Farm, and were bred at 24 ° C. ± 1 ° C. for 1 week and weighed 24 ± 2 g.
2) 실험방법2) Experiment Method
ICR계 쥐(mouse) 수컷 6마리를 한 군으로 하여 경구 투여전에 체중을 달고 3일 동안 1일3회 경구투여하면서 2일째부터는 마지막 경구투여 1시간 후 1일 3회 다시 체중을 측정하였고 그 결과를 하기 표 8 및 도 10에 나타내었다.Six male ICR mice were weighed before oral administration and administered orally three times a day for three days, and then weighed again three times a day after the last oral dose from day two. Are shown in Table 8 and FIG.
대조군: 50mg/kg 스트렙토조토신(streptozotocin ip)Control: 50 mg / kg streptozotocin (streptozotocin ip)
각 값은 ± S.E(N=6)을 나타낸다.Each value represents ± S.E (N = 6).
음성대조군과의 유의적 차이: *p<0.05Significant difference from negative control: * p <0.05
상기 표 8에서 알 수 있듯이, 대조군은 21.8± 1.9g에서 23.1± 3.0g으로 체중이 증가되었고, 실시예 2의 100mg/Kg투여군에서는 24.2± 2.6g에서 23.0± 0.5g으로 감소되었으나 유의성은 없었으며, 실시예 2의 200mg/Kg투여한 군에서는 22.7± 0.9g에서 20.5± 2.7g으로 감소되었으나 역시 유의성은 없었으며, 실시예 2의 400mg/Kg투여한 군에서는 22.2± 4.9g에서 18.9± 4.4g으로 유의성있는 체중감소를 보였다.As can be seen in Table 8, the control group gained weight from 21.8 ± 1.9 g to 23.1 ± 3.0 g, and in the 100 mg / Kg administration group of Example 2 was reduced from 24.2 ± 2.6 g to 23.0 ± 0.5 g, but there was no significant In the 200 mg / Kg administered group of Example 2, it was reduced from 22.7 ± 0.9 g to 20.5 ± 2.7 g, but there was no significance, and in the 400 mg / Kg administered group of Example 2, 28.9 ± 4.9 g and 18.9 ± 4.4 g, respectively. Significant weight loss.
본 발명에 따른 항당뇨 및 다이어트에 효과적인 기능성 식품은 항산화 작용 및 소장에서 탄수화물 및 지방에 대하여 상경적으로 작용해 흡수를 저해하고, 또한 흡수되어 혈중 글루코스(glucose), 트리글리세라이트(triglyceride) 및 콜레스테롤(cholesterol)치를 낮추는 생약으로 식품으로 사용될 수 있는 것 백감장, 미삼, 연자육, 우절, 사과락, 귤핵, 곤포, 길경 및 금은화를 조합하여 항산화 비만억제, 다이어트식품, 당뇨병예방 작용이 우수한 효과가 있다.Functional foods effective for anti-diabetic and diet according to the present invention is antioxidant and inhibits absorption by carbohydrates and fats in the small intestine and inhibits absorption, and also absorbs blood glucose, triglyceride and cholesterol Herbal medicine that lowers cholesterol and can be used as food. Antioxidant obesity inhibitor, diet food, and diabetes prevention effect are excellent in combination with white baekjang, ginseng, lotus root, chopsticks, apple rock, tangerine core, packing, gilyeong and gold and silver coin. .
상기에서 본 발명은 기재된 구체예를 중심으로 상세히 설명되었지만, 본 발명의 범주 및 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당 업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.While the present invention has been described in detail with reference to the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the scope and spirit of the present invention, and such modifications and variations are included in the appended claims. It is natural to belong.
도 1은 본발명의 실시예들에 대하여 실시한 항산화능측정 단계를 나타낸 모식도이다.1 is a schematic diagram showing the antioxidant activity measurement step performed for the embodiments of the present invention.
도 2는 본발명의 실시예들에 대하여 Cu2+에 의해 유도되는 과산화지질의 TBARS 분석방법을 나타낸 모식도이다.Figure 2 is a schematic diagram showing the TBARS analysis method of lipid peroxide induced by Cu 2+ for the embodiments of the present invention.
도 3은 본발명의 실시예들에 대하여 DPPH에 의한 항산화능 측정을 나타낸 그래프이다.Figure 3 is a graph showing the antioxidant capacity measurement by DPPH for the embodiments of the present invention.
도 4는 본발명의 실시예들에 대하여 DPPH에 의한 IC50값을 나타낸 그래프이다.4 is a graph showing IC 50 values by DPPH for the embodiments of the present invention.
도 5는 본발명의 실시예들에 대하여 Cu2+에 의해 유도되는 과산화지질의 억제효과를 나타낸 그래프이다.5 is a graph showing the inhibitory effect of lipid peroxide induced by Cu 2+ for the embodiments of the present invention.
도 6은 본발명의 실시예들에 대하여 Cu2+에 의해 유도되는 과산화지질의 억제에 대한 IC50값을 나타낸 그래프이다.FIG. 6 is a graph showing IC 50 values for the inhibition of lipid peroxide induced by Cu 2+ for embodiments of the present invention.
도 7은 스트렙토조토신(streptozotocin)에 의해 고혈당이 유도된 쥐에서 본 발명의 실시예들을 투여시 혈당에 미치는 영향을 나타낸 그래프이다.Figure 7 is a graph showing the effect on blood glucose when administering the embodiments of the present invention in mice hyperglycemia induced by streptozotocin (streptozotocin).
도 8 은 스트렙토조토신(streptozotocin)에 의해 고혈당이 유도된 쥐에서 본 발명의 실시예들을 투여시 혈중 콜레스테롤에 미치는 영향을 나타낸 그래프이다.Figure 8 is a graph showing the effect on blood cholesterol upon administration of the embodiments of the present invention in mice hyperglycemia induced by streptozotocin (streptozotocin).
도 9 은 스트렙토조토신(streptozotocin)에 의해 고혈당이 유도된 쥐에서 본 발명의 실시예들을 투여시 혈중 트리글리세라이드 양에 미치는 영향을 나타낸 그래프이다.Figure 9 is a graph showing the effect on the amount of triglycerides in the administration of the embodiments of the present invention in mice hyperglycemia induced by streptozotocin (streptozotocin).
도 10은 본발명의 실시예들을 투여한 군들의 체중감소효과를 나타낸 그래프이다.10 is a graph showing the weight loss effect of the groups administered the embodiments of the present invention.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030064952A KR20050028272A (en) | 2003-09-18 | 2003-09-18 | Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030064952A KR20050028272A (en) | 2003-09-18 | 2003-09-18 | Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050028272A true KR20050028272A (en) | 2005-03-22 |
Family
ID=37385265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030064952A KR20050028272A (en) | 2003-09-18 | 2003-09-18 | Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20050028272A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100888068B1 (en) * | 2007-04-19 | 2009-03-11 | 학교법인 동의학원 | Compositions for suppressing obesity |
KR100973195B1 (en) * | 2008-04-14 | 2010-07-30 | 오수진 | Composition containing complex oriental medicine extract for prevention and treatment of cardiovascular disease |
US8753693B2 (en) * | 2007-12-10 | 2014-06-17 | Lvmh Recherche | Cosmetic composition containing an extract from lotus and method of cosmetic care using said composition |
-
2003
- 2003-09-18 KR KR1020030064952A patent/KR20050028272A/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100888068B1 (en) * | 2007-04-19 | 2009-03-11 | 학교법인 동의학원 | Compositions for suppressing obesity |
US8753693B2 (en) * | 2007-12-10 | 2014-06-17 | Lvmh Recherche | Cosmetic composition containing an extract from lotus and method of cosmetic care using said composition |
KR100973195B1 (en) * | 2008-04-14 | 2010-07-30 | 오수진 | Composition containing complex oriental medicine extract for prevention and treatment of cardiovascular disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
CN102511869A (en) | Thickened red jujube ginger pulp | |
CN108835638A (en) | A kind of Soboring-up liver-protecting improves the food and preparation method thereof of immunity | |
CN110051815A (en) | A kind of auxiliary hyperglycemic food ball and preparation method thereof | |
KR100591539B1 (en) | Dietary supplement composition | |
KR20120010464A (en) | Composition having herb extract as active incredient for treating hangover and preparation method thereof | |
KR20040095949A (en) | Composition comprising herb with usage to prevent obeseness | |
CN112544767A (en) | Preparation method of selenium-rich tabletted candy | |
Jagtap et al. | Trigonella foenum graecum (Fenugreek): An Herb with Impressive Health Benefits and Pharmacological Therapeutic Effects | |
CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
KR100419185B1 (en) | Healty food composition for obesity control | |
CN114947129A (en) | Uric acid-reducing cichorium grandiflorum and angelica dahurica health food and preparation method thereof | |
CN109275906A (en) | The preparation method of one kind of multiple plant compounding anoretics | |
KR20050028272A (en) | Functional food prepared from combined prescription having an effects on diet, diabetes, hyperlipemia and radical scavenging | |
CN106266687A (en) | A kind of health product for treating hypertension and chronic constipation | |
GB2446373A (en) | Natural laxative composition for treating and preventing constipation with colon cleansing action | |
CN105106721A (en) | Health product with efficacy of reducing blood sugar | |
CN108967757A (en) | A kind of thickened red jujube ginger pulp production technology | |
CN109430640A (en) | A kind of drinks of relieving alcoholism and protecting liver | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
KR100497845B1 (en) | food having herbal medicine for assisting healthy and producing method thereof | |
KR102671658B1 (en) | Dietary fiber composition for promoting defecation and improving cholesterol containing psyllium hull and manufacturing method thereof | |
KR101154182B1 (en) | Natural beverage composition prescribed based on patient's physical constitution | |
KR20140046141A (en) | Anti obesity composition | |
KR20040010854A (en) | Manufacture method, Various uses and Extracts for The Development of Anticonspitation Functional food materials from Oriental Herbal Medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |